Fondation Ophtalmologique Adolphe de Rothschild

Quick facts

Marketed products

• Budesonide Nasal
• injection of NMBA · Anesthesia
  NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.

Phase 3 pipeline

• addition of rituximab if recurrence
• immediate treatment with corticosteroids · Ophthalmology / Immunology
  Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• Ocrelizumab Injection [Ocrevus] · Immunology / Neurology
  Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.

Phase 2 pipeline

• Administration of dornase alfa · Respiratory
  Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.
• Daily infusion of dornase alfa · Pulmonary/Respiratory
  Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.

Phase 1 pipeline

• Atropine 0.05% eyedrops

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Fondation Ophtalmologique Adolphe de Rothschild portfolio CI brief
• Fondation Ophtalmologique Adolphe de Rothschild pipeline updates RSS